tetano
Editor, Senior Moderator
Virology. 2014 Jan 5;448:159-67. doi: 10.1016/j.virol.2013.10.010. Epub 2013 Oct 25.
Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants.
Kawano M, Morikawa K, Suda T, Ohno N, Matsushita S, Akatsuka T, Handa H, Matsui M.
Source
Department of Allergy and Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-cho, Iruma-gun, Saitama 350-0495, Japan.
Abstract
Virus-like particles (VLPs) are a promising vaccine platform due to the safety and efficiency. However, it is still unclear whether polyomavirus-based VLPs are useful for this purpose. Here, we attempted to evaluate the potential of polyomavirus VLPs for the antiviral vaccine using simian virus 40 (SV40). We constructed chimeric SV40-VLPs carrying an HLA-A(⁎)02:01-restricted, cytotoxic T lymphocyte (CTL) epitope derived from influenza A virus. HLA-A(⁎)02:01-transgenic mice were then immunized with the chimeric SV40-VLPs. The chimeric SV40-VLPs effectively induced influenza-specific CTLs and heterosubtypic protection against influenza A viruses without the need of adjuvants. Because DNase I treatment of the chimeric SV40-VLPs did not disrupt CTL induction, the intrinsic adjuvant property may not result from DNA contaminants in the VLP preparation. In addition, immunization with the chimeric SV40-VLPs generated long-lasting memory CTLs. We here propose that the chimeric SV40-VLPs harboring an epitope may be a promising CTL-based vaccine platform with self-adjuvant properties.
? 2013 Elsevier Inc. All rights reserved.
KEYWORDS:
Adjuvant, Cytotoxic T lymphocyte, Influenza A virus, Polyomavirus, SV40, Vaccine, Virus-like particles
PMID:
24314646
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/24314646
Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants.
Kawano M, Morikawa K, Suda T, Ohno N, Matsushita S, Akatsuka T, Handa H, Matsui M.
Source
Department of Allergy and Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-cho, Iruma-gun, Saitama 350-0495, Japan.
Abstract
Virus-like particles (VLPs) are a promising vaccine platform due to the safety and efficiency. However, it is still unclear whether polyomavirus-based VLPs are useful for this purpose. Here, we attempted to evaluate the potential of polyomavirus VLPs for the antiviral vaccine using simian virus 40 (SV40). We constructed chimeric SV40-VLPs carrying an HLA-A(⁎)02:01-restricted, cytotoxic T lymphocyte (CTL) epitope derived from influenza A virus. HLA-A(⁎)02:01-transgenic mice were then immunized with the chimeric SV40-VLPs. The chimeric SV40-VLPs effectively induced influenza-specific CTLs and heterosubtypic protection against influenza A viruses without the need of adjuvants. Because DNase I treatment of the chimeric SV40-VLPs did not disrupt CTL induction, the intrinsic adjuvant property may not result from DNA contaminants in the VLP preparation. In addition, immunization with the chimeric SV40-VLPs generated long-lasting memory CTLs. We here propose that the chimeric SV40-VLPs harboring an epitope may be a promising CTL-based vaccine platform with self-adjuvant properties.
? 2013 Elsevier Inc. All rights reserved.
KEYWORDS:
Adjuvant, Cytotoxic T lymphocyte, Influenza A virus, Polyomavirus, SV40, Vaccine, Virus-like particles
PMID:
24314646
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/24314646